Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.

Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 10; 6(10):816-825.

View in: PubMed

subject areas

Adalimumab
Adult
Antibodies, Monoclonal
Biosimilar Pharmaceuticals
Crohn Disease
Double-Blind Method
Europe
Female
Humans
Injections, Subcutaneous
Male
Middle Aged
Safety
Severity of Illness Index
Treatment Outcome
United States

authors with profiles

Stephen B. Hanauer